Background
==========

Pemphigus vulgaris (PV) is a severe autoimmune blistering skin disorder due to loss of integrity of normal intercellular attachments within the epidermis and mucosal epithelium. Strong association of PV to the major histocompatibility complex (MHC) class II alleles DRB1\*0402 and DQB1\*0503 have been reported in the literature \[[@B1]-[@B6]\] with over 95% of PV patients possessing one or both of these alleles \[[@B7],[@B8]\]. The molecular basis and immunological consequences of this dual HLA association has thus far not been elucidated. The target antigen of PV, desmoglein (Dsg) 3, is a 130-kDa transmembrane glycoprotein that belongs to the cadherin superfamily of cell adhesion molecules \[[@B9]\]. In the early stage of disease, patients demonstrate autoimmunity only to Dsg3 and develop mucosal blisters; while at the later stage, patients exhibit non-cross-reactive immunity to both Dsg3 and Dsg1 \[[@B10]\]. Despite several reports of T-cell specificities within Dsg3 \[[@B11]-[@B16]\], the number is limited and the role of T-cells in the pathogenesis of PV remains poorly understood.

Bioinformatic tools are now commonly used in facilitating T-cell epitope discovery \[[@B17]-[@B19]\]. Computational methods for predicting MHC-binding peptides include procedures based on sequence motifs \[[@B13],[@B16]\], quantitative matrices \[[@B20]-[@B22]\], decision trees \[[@B23],[@B24]\], artificial neural networks \[[@B25],[@B26]\], hidden Markov models \[[@B27]\] and support vector machines \[[@B28]-[@B30]\]. However, despite recent advances in sequence-based predictive techniques, effective models for DRB1\*0402 and DQB1\*0503 have been lacking, mainly due to the paucity of sufficient peptides as training data \[[@B31]\] as well as register-shifts (or positional differences between the core nonameric peptide in the binding groove) \[[@B31]\] and polymorphisms in the binding registers (A.A. Sinha, unpublished results). To date, few prediction techniques for MHC class II molecules have been developed using three-dimensional models as the dual issues of model quality and discrimination technique must be addressed \[[@B32]\].

Our strategy for prediction of T-cell epitopes involves the three-dimensional modeling of peptide/MHC complexes using a hybrid docking approach that integrates the strengths of Monte Carlo simulations and homology modeling \[[@B31],[@B33],[@B34]\]. In an earlier study, we have successfully discriminated disease-implicated from non-disease implicated and protective alleles in PV based on structural interaction rules \[[@B31]\]. A complementary scoring function has now been developed for effective identification of DRB1\*0402 and DQB1\*0503 epitopes. We investigated the T-cell epitope repertoire of the entire Dsg3 glycoprotein and show the existence of multiple extracellular and intracellular specificities within the Dsg3 self-antigen. Further analysis reveal that DRB1\*0402 and DQB1\*0503 share similar specificities by binding peptides at different core recognition regions. These data provide a molecular rationale for the association of PV to two distinct HLA molecules and impact our understanding of the mechanism of HLA mediated control of disease.

Results and Discussion
======================

DRB1\*0402 predictive model
---------------------------

The DRB1\*0402 model shows excellent correlation with experimental binding affinities (*r*^2^= 0.90, *s*= 1.20 kJ/mol, *q*^2^= 0.82, *s*~*press*~= 1.61 kJ/mol). The accuracy of the prediction model was further evaluated using (i) peptides with experimental IC~50~values obtained from biochemical studies and (ii) Dsg3 peptides with T-cell proliferation values obtained from functional studies.

Three threshold binding energy values (Table [1](#T1){ref-type="table"}) that define levels of specificities suitable for practical applications \[[@B34]\] were used to evaluate the accuracy of the DRB1\*0402 prediction model on the biochemical dataset (Test set 1) -- LMH (low-, medium-, high-affinity binders; A~ROC~= 0.93); MH (medium- and high-affinity binders; A~ROC~= 0.86) and H (high-affinity binders only; A~ROC~= 0.81). The results indicate that, overall, our DRB1\*0402 peptide-binding models are highly accurate (A~ROC~= 0.93). SP = 0.80 offers high-sensitivity predictions, whereas SP = 0.95 results in very few false positives but fewer true positives. The prediction results for our model were consistent with expected binding patterns of DRB1\*0402 peptides and provided a sensitivity of 70% (SP = 0.95) for DRB1\*0402-binding peptides.

Next, the predictive performance of the DRB1\*0402 model was tested on the functional dataset of 25 peptides (Test set 2) with experimental T-cell proliferation values/responses using the decision thresholds defined above. All experimental positives (Table [2](#T2){ref-type="table"}) are predicted with binding energy values of -26.64 kJ/mol or less (high-affinity binders; SE = 0.65, SP = 0.80). Our simulation results indicate that DRB1\*0402 can bind Dsg3 96--112 at threshold -26.64 kJ/mol (SE = 0.65, SP = 0.80) in contrast to previous qualitative study results \[[@B31]\], albeit at a binding energy (-27.09 kJ/mol) close to the threshold. Dsg3 512--526 (ranked \#10), Dsg3 78--93 (ranked \#12) and Dsg3 96--110 (ranked \#19) are predicted binders (SE = 0.65, SP = 0.80) that did not stimulate T-cell responses in the relevant experiments \[[@B11],[@B13],[@B16]\]. Noteworthy, peptides Dsg3 78--93 \[[@B13]\] and Dsg3 96--110 \[[@B16]\] are fully contained within Dsg3 78--94 (ranked \#11) and Dsg3 96--112 (ranked \#22), both of which are experimental true positives identified in an independent study \[[@B11]\]. For Dsg3 78--93, the preferred binding register identified by our models is 79--87, which is shows a 5-residue shift in the binding register from the preferred core of 82--90 for Dsg3 78--94. There is no change in the binding register observed for Dsg3 96--110 and Dsg3 96--112. It is possible that variability in the binding register (\#12) or flanking peptide residues (\#19) lead to a change in T-cell stimulation.

DQB1\*0503 predictive model
---------------------------

The DQB1\*0503 prediction model correlate well with experimental data (*r*^2^= 0.95, *s*= 1.20 kJ/mol). The DQB1\*0503 model outperforms the prediction models done by Rognan *et al*. (1999) on training datasets of 5 HLA-A\*0204 (*r*^2^= 0.85, *s*~*press*~= 2.40 kJ/mol) and 37 H2-K^k^(*r*^2^= 0.78, *s*~*press*~= 3.16 kJ/mol) peptide sequences and is consistent with our DRB1\*0402 prediction model (*r*^2^= 0.90, *s*= 1.20 kJ/mol, *q*^2^= 0.82, *s*~*press*~= 1.61 kJ/mol) which is trained using the same number of data points. The cross-validation coefficient *q*^2^and the standard error of prediction *s*~*press*~are stable, with *q*^2^= 0.75 and *s*~*press*~= 2.15 kJ/mol. This iterative regression procedure validates the internal consistency of the scoring function in the current model, rendering it suitable for predictions on the test dataset obtained from functional studies.

The accuracy of the DQB1\*0503 prediction model was assessed on a dataset of 6 (5 stimulatory and 1 non-stimulatory peptides) Dsg3 peptides with known T-cell proliferation values (Table [3](#T3){ref-type="table"}). All DQB1\*0503-specific Dsg3 stimulatory peptides can be effectively discriminated from the background at the prediction threshold -26.64 kJ/mol.

Disease progression in PV
-------------------------

A variety of studies have demonstrated that a limited set of epitopes may be present in early disease, and intra-molecular epitope spreading may occur during disease transition at the B-cell level \[[@B10]\]. Our data support the existence of multiple immunodominant T-cell epitopes that may be responsible for both disease initiation and propagation (Figure [1](#F1){ref-type="fig"} and Figure [2](#F2){ref-type="fig"}). These findings are in line with T-cell proliferation data obtained from DR4 and DR6 PV patients \[[@B11],[@B13],[@B15],[@B16],[@B31]\]. Our analysis showed that the potential Dsg3 T-cell epitope repertoire is well distributed throughout all five extracellular domains (ECDs) (ECD1: Dsg3 50--158; ECD2: Dsg3 159--268; ECD3: Dsg3 269--383; ECD4: Dsg3 386--499; ECD5: Dsg3 500--615) \[[@B35]\]. A large number of DQB1\*0503-specific Dsg3 peptides were predicted to exist within the transmembrane region (Dsg3 616--640; Figure [2](#F2){ref-type="fig"}). Noteworthy, 13 of these peptides were found among the top 20 predictions (Table [4](#T4){ref-type="table"}), suggesting that disease initiation may begin at the transmembrane region for DR6 PV patients. Such an initiation step would not be unique to PV as other studies have revealed disease initiation at the transmembrane region \[[@B36],[@B37]\]. For DRB1\*0402, 90% (18/20) of the top 20 predictions were predicted to exist within the ECDs, suggesting that disease initiation in DR4 and DR6 PV patients may be different. Although two DRB1\*0402-specific intracellular peptides (Dsg3 762--786, Dsg3 786--800) have been reported \[[@B13],[@B16]\], and were correctly detected by our model (SP = 0.80, SE = 0.65), relatively few intracellular peptides from the region, Dsg3 641--999, are predicted by our methods. It remains to be determined what proportion of the predicted epitopes are actually generated via antigen processing events *in vivo*, or remain subdominant or \"cryptic\", such that they are not available for recognition during the initial immune response. It is likely that immune responses develop against secondary epitopes at later stages of disease progression, as a result of intramolecular epitope spreading, and it will be important to delineate the cascade of disease relevant epitopes in temporal sequence in future work.

DRB1\*0402 and DQB1\*0503 cross reactivity
------------------------------------------

An in-depth analysis was performed to investigate the extent of overlap in the Dsg3 peptide-binding repertoires of DRB1\*0402 and DQB1\*0503. A panel of 936 15mer Dsg3 sequences were generated using an overlapping sliding window of size 15 across the entire Dsg3 glycoprotein and modeled into the binding grooves of both DRB1\*0402 and DQB1\*0503 (explained in detail in *Peptide docking*).

Both the DRB1\*0402 and DQB1\*0503 alleles are particularly efficient in binding Dsg3-derived peptides. Furthermore, a significant level of cross-reactivity was observed between DRB1\*0402 and DQB1\*0503. Of the 936 overlapping 15mer peptides generated from the entire Dsg3 glycoprotein investigated in this study, 539 (57%) were predicted high-affinity binders to both alleles at threshold -26.64 kJ/mol. The computer simulation results are shown in Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}. Noteworthy, three previously defined immunoreactive segments of the Dsg3 extracellular domains (Dsg3 145--192, 240--303 and 570--614) \[[@B38]\] were also predicted by our models at this specific threshold. Among the known Dsg3 peptides (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}), only 2 (Dsg3 191--205 and 762--776) were predicted to bind DRB1\*0402 alone, consistent with our earlier qualitative results from structural studies alone \[[@B31]\]. 18 (Dsg3 78--94, 96--112, 161--177, 189--205, 190--204, 205--221, 206--220, 210--226, 250--266, 251--265, 342--356, 342--358, 376--392, 380--396, 483--499, 786--800, 810--824, 963--977) were predicted to bind to both DRB1\*0402 and DQB1\*0503. These observations are of particular interest in that both DRB1\*0402 and DQB1\*0503 are strongly linked to PV \[[@B39],[@B40]\], indicating that common or overlapping dominant epitopes may be responsible for inducing disease in DR4 and DR6 patients respectively.

DRB1\*0402 and DQB1\*0503 peptide binding specificities
-------------------------------------------------------

The basis for the high degree of cross-reactivities between DRB1\*0402 and DQB1\*0503 was subjected to further analysis. Our data support the existence of multiple binding registers within a candidate binding peptide that serve as recognition sites for DRB1\*0402 and DQB1\*0503, an observation previously noted for DQB1\*0302 binding peptides \[[@B34]\]. Of 936 Dsg3 sequences, 614 were predicted high-affinity binders with 76% displaying 2 or more registers that can be docked into the binding groove of DRB1\*0402 (Figure [3](#F3){ref-type="fig"}). Similar results are obtained for DQB1\*0503, with 673 predicted high-affinity binders and 57% exhibiting 2 or more binding registers (Figure [3](#F3){ref-type="fig"}). DRB1\*0402 and DQB1\*0503 predicted consensus binding sequences number 539. A striking aspect of this analysis is that DRB1\*0402 and DQB1\*0503 were predicted to bind a large portion of these peptides (354/539 or 66%) at different binding registers. Noteworthy, this difference was detected in 70% (7/10) of Dsg3 peptides known to bind both DRB1\*0402 and DQB1\*0503 (Table [5](#T5){ref-type="table"}). For example, the consensus binding peptide Dsg 205--221 showed ΔG values less than the decision threshold -26.64 kJ/mol, with the 211--219 and 212--220 registers being the preferred binding modes for DRB1\*0402 and DQB1\*0503 respectively. We propose that DRB1\*0402 and DQB1\*0503 share similar specificities by binding peptides at different binding registers.

Conclusion
==========

Although PV was first reported by Hippocrates in 400 B.C., few T-cell specificities within Dsg3 have been identified to date \[[@B11]-[@B16]\], and the role of MHC and T-cells in the pathogenesis of PV still remains poorly understood. Collectively, the results of this study provide interesting new insights into the pathology of PV. This is the first report of high-level of cross-reactivity between both PV-implicated alleles, DRB1\*0402 and DQB1\*0503, as well as the existence of a potentially large number of T-cell epitopes throughout the entire Dsg3 ECD and transmembrane region. Our data strongly indicates that multiple initial epitopes may be responsible for both disease initiation and progression. In addition, our modelling results revealed that DR4 and DR6 PV may initiate at different regions of Dsg3. DR4 PV may initiate in the ECD while DR6 PV may begin at the transmembrane region. It remains to be determined what proportion of predicted DRB1\*0402 and DQB1\*0503 binders are capable of stimulating PV-implicated alleles and autoreactive T-cells. If experimental analysis reveals limited sets of predicted Dsg3 peptides capable of eliciting functional responses, control over autoreactivity may rest at the T-cell level, rather than the level of determinant selection by MHC molecules. This will have a direct impact in the design of immunotherapeutic strategies for the treatment of this autoimmune disease.

Methods
=======

MHC sequence data were obtained from IMGT-HLA database \[[@B41]\]. To identify potential structural templates available in the Protein Data Bank (PDB) \[[@B42]\] for model building, a sequence similarity search was performed using PSI-BLAST \[[@B43]\] running on the servers at NCBI and the highest quality templates (with the best resolution, highest sequence similarity and minimal number of missing residues) were selected among the returned results. The crystal structures of DRB1\*0401 (PDB code 1D5Z) and DQB1\*0602 (PDB code 1UVQ) were selected as templates for DRB1\*0402 (97.9% identity) and DQB1\*0503 (93.0% identity) respectively.

Model building
--------------

The program MODELLER \[[@B44]\] was employed for comparative modeling of both DRB1\*0402 and DQB1\*0503. The models are constructed by optimally satisfying spatial constraints obtained from the alignment of the template structure with the target sequence and from the CHARMM-22 force field \[[@B45]\]. The structures were relaxed by conjugate gradient minimization, using the Internal Coordinate Mechanics (ICM) 3.0 package \[[@B46]\].

Experimental binding data
-------------------------

Two sets of data are used in this study: (i) peptides with experimental IC~50~values from biochemical studies and (ii) peptides with experimental T-cell proliferation values/responses from functional studies.

Dataset I ([Additional file 1](#S1){ref-type="supplementary-material"}: Table S1) comprises 59 DRB1\*0402-specific peptides derived from biochemical studies (20 high-affinity, 11 medium-affinity and 13 low-affinity binders and 15 non-binders). Peptides are classified based on their experimental IC~50~values (high-affinity binders: IC~50~≤ 500 nM, medium-affinity binders: 500 nM \< IC~50~≤ 1500 nM, low-affinity binders: 1500 \< IC~50~≤ 5000 nM and non-binders: 5000 \< IC~50~).

Dataset II ([Additional file 2](#S2){ref-type="supplementary-material"}: Table S2) consists of 25 DRB1\*0402-specific Dsg3 peptides and 14 DQB1\*0503-specific Dsg3 peptides with T-cell proliferation values/responses \[[@B11]-[@B13]\].

Peptide docking
---------------

Overlapping 15-mer peptides are generated from the Dsg3 sequence. An overlapping sliding window of size nine is applied to each 15-mer peptide to generate all combinations of binding registers to be modeled into the binding grooves of DRB1\*0402 and DQB1\*0503. Docking was performed with the Empirical Conformational Energy Program for Peptides 3 force field parameters (ECEPP/3) \[[@B46]\] and MMFF partial charges \[[@B47]\] on a 4-CPU SGI Origin 3200 workstation using an extension of the protocol \[[@B33],[@B34]\]: (i) pseudo-Brownian rigid body docking of peptide fragments to the ends of the binding groove, (ii) central loop closure by satisfaction of spatial constraints, (iii) refinement of the backbone and side-chain atoms of the core recognition residues and receptor contact regions within 4.00Å radius \[[@B31],[@B33]\] and (iv) extension of flanking peptide residues by satisfaction of spatial constraints.

Empirical free energy functions
-------------------------------

The scoring function presented in this study is based on the free energy potential in ICM3.0 package \[[@B47]\]. The binding free energy function is partitioned into three terms \[[@B34]\] expressed by the equation:

ΔG = αΔG~H~+ βΔG~S~+ γΔG~EL~+ *C*.     (1)

ΔG~H~is the hydrophobic energy computed as the product of solvent accessible surface area (determined by rolling a sphere of 1.40Å radius along the surface of the molecule) by the surface tension. ΔG~S~refers to the entropic contribution from the protein side-chains computed from the maximal burial entropies for each type of amino acid and their relative accessibilities. ΔG~EL~denotes the electrostatic term composed of coulombic interactions between receptor and ligand and the desolvation of partial charges transferred from an aqueous medium to a protein core environment, and is determined by the numeric solution of the Poisson equation using an implementation of the boundary element algorithm \[[@B48]-[@B50]\]. The constant term *C*accounts for entropy change in the system due to the decrease of free molecular concentration and the loss of rotational/translational degrees of freedom upon binding \[[@B51]\].

Training, testing and validation
--------------------------------

Two computational models are trained in this study -- one model for the prediction of peptide binding to DRB1\*0402 and the other for DQB1\*0503.

DRB1\*0402-specific peptide data derived from biochemical studies with experimental IC~50~values was divided into training and test sets. The training set comprised 8 (5 binding and 3 non-binding) Dsg3 sequences with experimentally determined binding registers (from Dataset I). Two external sets of test data were used: (i) Test set 1: 51 peptides with experimental IC~50~values (20 high-affinity binders, 11 medium affinity binders, 9 low affinity binders and 11 non-binders) from biochemical studies, and (ii) Test set 2: all DRB1\*0402-specific Dsg3 peptides from Dataset II, with known T-cell proliferation values.

DQB1\*0503 prediction model was trained using Dsg3 peptide data from functional studies in the absence of relevant biochemical data. The training set comprised 8 (5 stimulatory and 3 non-stimulatory) sequences from Dataset II. For each peptide sequence, T-cell proliferation value \[[@B13]\] is mapped to a theoretical IC~50~value in accordance with expected binding patterns of Dsg3 binding peptides (Sinha *et al*., personal communications). The performance of the prediction model was subsequently evaluated on an external set of 6 peptides with known T-cell proliferation values.

Coefficients (α, β, γ) and the constant term *C*in Equation 1 were derived using standard least-square multivariate regression analyses of the training set, followed by leave-one-out analysis to assess to quality of the scoring function \[[@B52]\]. For each model, the entire procedure is repeated 8 times to reduce noises in all computations, the results averaged and the observed error rate is used to estimate the expected error rate upon generalization to new data.

The optimal scoring function selected from each cross-validation analysis was further assessed using sensitivity (SE), specificity (SP) and receiver operating characteristic (ROC) analysis \[[@B34]\]. SE = TP/(TP+FN) and SP = TN/(TN+FP), indicate percentages of correctly predicted binders and non-binders, respectively. TP (true positives) represents experimental binders with at least one predicted binding register and TN (true negatives) for experimental non-binders with no predicted binding register. FN (false negatives) denotes experimental binders predicted as non-binders and FP (false positives) represents experimental non-binders predicted as binders. The accuracy of our predictions was assessed by ROC analysis where the ROC curve is generated by plotting SE as a function of (1-SP) for various classification thresholds. The area under the ROC curve (A~ROC~) provides a measure of overall prediction accuracy, A~ROC~\<70% for poor, A~ROC~\>80% for good and A~ROC~\>90% for excellent predictions \[[@B34]\]. In this study, we assessed SE for three values of SP (80%, 90% and 95%) that are considered useful in practice. All regression and validation results, including correlation coefficient (*r*^2^), standard deviation (*s*), cross-validation coefficient (*q*^2^), standard error of prediction (*s*~press~), SE, SP, A~ROC~, coefficients and constant terms in the scoring function, are recorded.
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![**Predicted DRB1\*0402-specific T-cell epitope repertoire within Dsg3**. Location of predicted DRB1\*0402-specific T-cell epitopes along the Dsg3 glycoprotein -- extracellular domain (colored yellow; Dsg3 50--615), transmembrane region (colored green; Dsg3 616--640), and intracellular domain (colored pink; Dsg3 641--999). The red line indicates decision threshold -26.64 kJ/mol for high-affinity binders (SP = 0.80, SE = 0.65).](1471-2105-7-S5-S7-1){#F1}

![Predicted DQB1\*0503-specific T-cell epitope repertoire within Dsg3. Location of predicted DQB1\*0503-specific T-cell epitopes along the Dsg3 glycoprotein -- extracellular domain (colored yellow; Dsg3 50--615), transmembrane region (colored green; Dsg3 616--640), and intracellular domain (colored pink; Dsg3 641--999). The red line indicates decision threshold -26.64 kJ/mol for high-affinity binders (SP = 0.80, SE = 0.65).](1471-2105-7-S5-S7-2){#F2}

![Predicted binding registers for Dsg3 peptides bound to DRB1\*0402 and DQB1\*0503. The frequency of Dsg3 peptides docked to DRB1\*0402 (colored gray) and DQB1\*0503 (colored white) is shown as a function of the number of predicted binding registers.](1471-2105-7-S5-S7-3){#F3}

###### 

Prediction accuracy of the DRB1\*0402 peptide-binding model.

  **Specificity (SP) Level**   **Group**   **Sensitivity (SE)**   **Binding Energy Threshold (kJ/mol)**
  ---------------------------- ----------- ---------------------- ---------------------------------------
  SP = 0.80                    LMH         0.78                   -25.55
                               MH          0.81                   -25.79
                               H           0.65                   -26.64
  SP = 0.90                    LMH         0.75                   -25.79
                               MH          0.52                   -26.94
                               H           0.30                   -28.83
  SP = 0.95                    LMH         0.70                   -26.94
                               MH          0.42                   -27.72
                               H           0.25                   -30.57

Sensitivity (SE) values and binding energy thresholds for DRB1\*0402 peptide-binding model at specificity (SP) levels 0.80, 0.90 and 0.95.

###### 

Predicted binding affinities of Dsg3 peptide sequences to DRB1\*0402.

  **Rank**   **Peptide**     **Sequence**        **Predicted BE (kJ/mol)**   **References**
  ---------- --------------- ------------------- --------------------------- -------------------------------
  1          Dsg3 342--358   SVKLSIAVKNKAEFHQS   -31.46                      Veldman *et al*. (2004)
  2^\#^      Dsg3 342--356   SVKLSIAVKNKAEFH     -30.88                      Moesta *et al*. (2002)
  3          Dsg3 205--221   GTPMFLLSRNTGEVRTL   -30.44                      Veldman *et al*. (2004)
  4\* ^\#^   Dsg3 846--860   LDSLGPKFKKLAEIS     -30.17                      Moesta *et al*. (2002)
  5          Dsg3 380--396   GIAFRPASKTFTVQKGI   -29.97                      Riechers *et al*. (1999)
  6^@^       Dsg3 67--81     RNPIAKITSDYQATQ     -29.94                      Moesta *et al*. (2002)
  7          Dsg3 786--800   MNFLDSYFSQKAFAC     -29.78                      Moesta *et al*. (2002)
  8          Dsg3 190--204   LNSKIAFKIVSQEPA     -29.74                      Wucherpfennig *et al*. (1995)
  9          Dsg3 189--205   HLNSKIAFKIVSQEPAG   -29.24                      Veldman *et al*. (2004)
  10\*       Dsg3 512--526   SARTLNNRYTGPYTF     -29.21                      Wucherpfennig *et al*. (1995)
  11         Dsg3 78--94     QATQKITYRISGVGIDQ   -28.37                      Veldman *et al*. (2004)
  12\*       Dsg3 78--93     QATQKITYRISGVGID    -28.30                      Wucherpfennig *et al*. (1995)
  13         Dsg3 191--205   NSKIAFKIVSQEPAG     -28.16                      Moesta *et al*. (2002)
  14         Dsg3 206--220   TPMFLLSRNTGEVRT     -28.02                      Wucherpfennig *et al*. (1995)
  15         Dsg3 210--226   LLSRNTGEVRTLTNSL    -27.98                      Veldman *et al*. (2004)
  16         Dsg3 251--265   CECNIKVKDVNDNFP     -27.88                      Wucherpfennig *et al*. (1995)
  17         Dsg3 250--266   QCECNIKVKDVNDNFPM   -27.68                      Veldman *et al*. (2004)
  18         Dsg3 483--499   VRVPDFNDNCPTAVLEK   -27.48                      Veldman *et al*. (2004)
  19\* ^@^   Dsg3 96--110    PFGIFVVDKNTGDIN     -27.47                      Moesta *et al*. (2002)
  20         Dsg3 762--776   QSGTMRTRHSTGGTN     -27.28                      Wucherpfennig *et al*. (1995)
  21         Dsg3 161--177   IFMGEIEENSASNSLVM   -27.09                      Hertl *et al*. (1998)
  22         Dsg3 96--112    PFGIFVVDKNTGDINIT   -27.09                      Veldman *et al*. (2004)
  23^@^      Dsg3 963--977   ERVICPISSVPGNLA     -26.87                      Moesta *et al*. (2002)
  24\*       Dsg3 97--111    FGIFVVDKNTGDINI     -26.58                      Wucherpfennig *et al*. (1995)
  25^@^      Dsg3 810--824   NDCLLIYDNEGADAT     -24.00                      Moesta *et al*. (2002)

Predicted binding affinities of Dsg3 peptide sequences to DRB1\*0402. \'^\#^\', \'^@^\', **\'\*\'**indicate binding, non-binding and non-immunostimulatory in the relevant experiments respectively.

###### 

Predicted binding affinities of Dsg3 peptide sequences to DQB1\*0503.

  **Rank**   **Peptide**     **Sequence**                **Predicted BE (kJ/mol)**   **References**
  ---------- --------------- --------------------------- --------------------------- -------------------------------
  1          Dsg3 206--220   TPMFLLSRNTGEVRT             -30.53                      Wucherpfennig *et al*. (1995)
  2          Dsg3 189--205   HLNSKIAFKIVSQEPAG           -29.10                      Veldman *et al*. (2004)
  3          Dsg3 78--94     QATQKITYRISGVGIDQ           -27.14                      Veldman *et al*. (2004)
  4          Dsg3 190--204   LNSKIAFKIVSQEPA             -26.88                      Wucherpfennig *et al*. (1995)
  5          Dsg3 251--265   CECNIKVKDVNDNFP             -26.65                      Wucherpfennig *et al*. (1995)
  6\*        Dsg3 762--786   QSGTMRTRHSTGGTNKDYADGAISM   -22.42                      Wucherpfennig *et al*. (1995)

Predicted binding affinities of Dsg3 peptide sequences to DQB1\*0503. \'\*\' indicates non-immunostimulatory in the relevant experiments.

###### 

Top 20 predicted Dsg3 peptide sequences binding to DQB1\*0503 and DRB1\*0402.

  **Rank**   **DQB1\*0503**   **DRB1\*0402**                                                                     
  ---------- ---------------- ---------------------------- -------- --------------- ---------------------------- --------
  1          Dsg3 627--641    GLLLL**[LLAPLLLLT]{.ul}**C   -39.23   Dsg3 601--615   TT**[SPGTRYGRP]{.ul}**HSGR   -34.64
  2          Dsg3 626--640    LGLL**[LLLLAPLLL]{.ul}**LT   -38.43   Dsg3 263--277   N**[FPMFRDSQY]{.ul}**SARIE   -33.86
  3          Dsg3 624--638    LLLG**[LLLLLLAPL]{.ul}**LL   -37.87   Dsg3 844--858   S**[FLDSLGPKF]{.ul}**KKLAE   -33.46
  4          Dsg3 629--643    LLL**[LLAPLLLLT]{.ul}**CDC   -37.82   Dsg3 264--278   F**[PMFRDSQYS]{.ul}**ARIEE   -33.22
  5          Dsg3 625--639    LLGL**[LLLLLAPLL]{.ul}**LL   -37.65   Dsg3 599--613   Y**[PTTSPGTRY]{.ul}**GRPHS   -33.10
  6          Dsg3 628--642    LLLL**[LLAPLLLLT]{.ul}**CD   -37.47   Dsg3 352--366   KAEFHQ**[SVISRYRVQ]{.ul}**   -32.88
  7          Dsg3 620--634    AIG**[LLLLGLLLL]{.ul}**LLA   -36.48   Dsg3 598--612   S**[YPTTSPGTR]{.ul}**YGRPH   -32.76
  8          Dsg3 623--637    LLLLGL**[LLLLLAPLL]{.ul}**   -36.44   Dsg3 442--456   AEIKF**[VKNMNRDST]{.ul}**F   -32.60
  9          Dsg3 618--632    PA**[AIGLLLLGL]{.ul}**LLLL   -36.36   Dsg3 440--454   KTA**[EIKFVKNMN]{.ul}**RDS   -32.56
  10         Dsg3 293--307    LD**[EEYTDNWLA]{.ul}**VYFF   -36.28   Dsg3 439--453   SKT**[AEIKFVKNM]{.ul}**NRD   -32.36
  11         Dsg3 622--636    GLLL**[LGLLLLLLA]{.ul}**PL   -36.23   Dsg3 52--66     VKFAK**[PCREGEDNS]{.ul}**K   -32.13
  12         Dsg3 619--633    AA**[IGLLLLGLL]{.ul}**LLLL   -36.20   Dsg3 186--200   EPN**[HLNSKIAFK]{.ul}**IVS   -32.10
  13         Dsg3 294--308    DE**[EYTDNWLAV]{.ul}**YFFT   -36.15   Dsg3 354--368   E**[FHQSVISRY]{.ul}**RVQST   -32.10
  14         Dsg3 621--635    IGLLL**[LGLLLLLLA]{.ul}**P   -35.67   Dsg3 247--261   LSTQC**[ECNIKVKDV]{.ul}**N   -32.08
  15         Dsg3 297--311    YTDNWL**[AVYFFTSGN]{.ul}**   -35.28   Dsg3 262--276   DNF**[PMFRDSQYS]{.ul}**ARI   -32.07
  16         Dsg3 483--497    VRVP**[DFNDNCPTA]{.ul}**VL   -35.17   Dsg3 845--859   F**[LDSLGPKFK]{.ul}**KLAEI   -32.07
  17         Dsg3 616--630    LGPA**[AIGLLLLGL]{.ul}**LL   -34.86   Dsg3 954--968   LL**[TQNVIVTER]{.ul}**VICP   -31.93
  18         Dsg3 317--331    EIQTD**[PRTNEGILK]{.ul}**V   -34.75   Dsg3 351--365   NKA**[EFHQSVISR]{.ul}**YRV   -31.87
  19         Dsg3 295--309    EEY**[TDNWLAVYF]{.ul}**FTS   -34.67   Dsg3 344--358   K**[LSIAVKNKA]{.ul}**EFHQS   -31.85
  20         Dsg3 136--150    DVEK**[PLILTVKIL]{.ul}**DI   -34.63   Dsg3 441--455   TA**[EIKFVKNMN]{.ul}**RDST   -31.72

The nonameric core peptide in the binding groove is shown in bold, underlined text.

###### 

Preferred binding registers of experimentally determined Dsg3 peptides for PV implicated alleles.

  **Peptide**     **Allele**   **Sequence**                   **Peptide**     **Allele**   **Sequence**
  --------------- ------------ ------------------------------ --------------- ------------ ------------------------------
  Dsg3 78--94     DRB1\*0402   QA**[TQKITYRIS]{.ul}**GVGIDQ   Dsg3 250--266   DRB1\*0402   QC**[ECNIKVKDV]{.ul}**NDNFPM
                  DQB1\*0503   QATQ**[KITYRISGV]{.ul}**GIDQ                   DQB1\*0503   QCECNIK**[VKDVNDNFP]{.ul}**M
  Dsg3 96--112    DRB1\*0402   PFGI**[FVVDKNTGD]{.ul}**INIT   Dsg3 251--265   DRB1\*0402   C**[ECNIKVKDV]{.ul}**NDNFP
                  DQB1\*0503   PFGIFV**[VDKNTGDIN]{.ul}**IT                   DQB1\*0503   CECNIK**[VKDVNDNFP]{.ul}**
  Dsg3 161--177   DRB1\*0402   IFMGEI**[EENSASNSL]{.ul}**VM   Dsg3 342--356   DRB1\*0402   SVKL**[SIAVKNKAE]{.ul}**FH
  Dsg3 189--205   DRB1\*0402   H**[LNSKIAFKI]{.ul}**VSQEPAG   Dsg3 342--358   DRB1\*0402   SVK**[LSIAVKNKA]{.ul}**EFHQS
                  DQB1\*0503   H**[LNSKIAFKI]{.ul}**VSQEPAG                   DQB1\*0503   SVKLS**[IAVKNKAEF]{.ul}**HQS
  Dsg3 190--204   DRB1\*0402   LNS**[KIAFKIVSQ]{.ul}**EPA     Dsg3 376--392   DQB1\*0503   NVR**[EGIAFRPAS]{.ul}**KTFTV
                  DQB1\*0503   LNS**[KIAFKIVSQ]{.ul}**EPA     Dsg3 380--396   DRB1\*0402   GIA**[FRPASKTFT]{.ul}**VQKGI
  Dsg3 191--205   DRB1\*0402   NSKIA**[FKIVSQEPA]{.ul}**G     Dsg3 483--499   DRB1\*0402   VRVPD**[FNDNCPTAV]{.ul}**LEK
  Dsg3 205--221   DRB1\*0402   GTPMFL**[LSRNTGEVR]{.ul}**TL   Dsg3 762--776   DRB1\*0402   QSGTM**[RTRHSTGGT]{.ul}**N
                  DQB1\*0503   GTPMFLL**[SRNTGEVRT]{.ul}**L   Dsg3 786--800   DRB1\*0402   MNFLDS**[YFSQKAFAC]{.ul}**
  Dsg3 206--220   DRB1\*0402   TPM**[FLLSRNTGE]{.ul}**VRT     Dsg3 810--824   DRB1\*0402   ND**[CLLIYDNEG]{.ul}**ADAT
                  DQB1\*0503   TPMFL**[LSRNTGEVR]{.ul}**T     Dsg3 963--977   DRB1\*0402   ERVICP**[ISSVPGNLA]{.ul}**
  Dsg3 210--226   DRB1\*0402   LLS**[RNTGEVRTL]{.ul}**TNSL                                 

Preferred binding registers of experimentally determined Dsg3 peptides for PV implicated alleles. Best fitting registers with lowest predicted binding energies are in bold, underlined text.
